Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,656 JPY | +3.40% | +5.39% | -0.28% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.28% | 2.3B | C+ | ||
+17.35% | 71.39B | C+ | ||
+2.39% | 25.1B | C+ | ||
+5.38% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
+0.49% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 9987 Stock
- Ratings Suzuken Co., Ltd.